 |
PDBsum entry 2hdr
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nat Chem Biol
2:720-723
(2006)
|
|
PubMed id:
|
|
|
|
|
| |
|
Deconstructing fragment-based inhibitor discovery.
|
|
K.Babaoglu,
B.K.Shoichet.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Fragment-based screens test multiple low-molecular weight molecules for binding
to a target. Fragments often bind with low affinities but typically have better
ligand efficiencies (DeltaG(bind)/heavy atom count) than traditional screening
hits. This efficiency, combined with accompanying atomic-resolution structures,
has made fragments popular starting points for drug discovery programs.
Fragment-based design adopts a constructive strategy: affinity is enhanced
either by cycles of functional-group addition or by joining two independent
fragments together. The final inhibitor is expected to adopt the same geometry
as the original fragment hit. Here we consider whether the inverse,
deconstructive logic also applies--can one always parse a higher-affinity
inhibitor into fragments that recapitulate the binding geometry of the larger
molecule? Cocrystal structures of fragments deconstructed from a known
beta-lactamase inhibitor suggest that this is not always the case.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Interacting side chains and active site Ser64 are shown as
sticks to orient the viewer. The unbiased F[o] – F[c] electron
density is also shown, contoured at 3 .
|
 |
Figure 4.
Shown is crystal structure of fragment F4 (purple carbons)
overlaid on that of the lead L1 (white carbons).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Chem Biol
(2006,
2,
720-723)
copyright 2006.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
Y.Huang,
and
A.Dömling
(2011).
The Gewald multicomponent reaction.
|
| |
Mol Divers,
15,
3.
|
 |
|
|
|
|
 |
B.B.Yan,
M.Z.Xue,
B.Xiong,
K.Liu,
D.Y.Hu,
and
J.K.Shen
(2009).
ScafBank: a public comprehensive Scaffold database to support molecular hopping.
|
| |
Acta Pharmacol Sin,
30,
251-258.
|
 |
|
|
|
|
 |
C.P.Mpamhanga,
D.Spinks,
L.B.Tulloch,
E.J.Shanks,
D.A.Robinson,
I.T.Collie,
A.H.Fairlamb,
P.G.Wyatt,
J.A.Frearson,
W.N.Hunter,
I.H.Gilbert,
and
R.Brenk
(2009).
One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.
|
| |
J Med Chem,
52,
4454-4465.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.G.Teotico,
K.Babaoglu,
G.J.Rocklin,
R.S.Ferreira,
A.M.Giannetti,
and
B.K.Shoichet
(2009).
Docking for fragment inhibitors of AmpC beta-lactamase.
|
| |
Proc Natl Acad Sci U S A,
106,
7455-7460.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.E.de Kloe,
D.Bailey,
R.Leurs,
and
I.J.de Esch
(2009).
Transforming fragments into candidates: small becomes big in medicinal chemistry.
|
| |
Drug Discov Today,
14,
630-646.
|
 |
|
|
|
|
 |
S.Chung,
J.B.Parker,
M.Bianchet,
L.M.Amzel,
and
J.T.Stivers
(2009).
Impact of linker strain and flexibility in the design of a fragment-based inhibitor.
|
| |
Nat Chem Biol,
5,
407-413.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.D.Snow
(2008).
Hunting for predictive computational drug-discovery models.
|
| |
Expert Rev Anti Infect Ther,
6,
291-293.
|
 |
|
|
|
|
 |
G.M.Rishton
(2008).
Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening.
|
| |
Curr Opin Chem Biol,
12,
340-351.
|
 |
|
|
|
|
 |
H.A.Carlson,
R.D.Smith,
N.A.Khazanov,
P.D.Kirchhoff,
J.B.Dunbar,
and
M.L.Benson
(2008).
Differences between high- and low-affinity complexes of enzymes and nonenzymes.
|
| |
J Med Chem,
51,
6432-6441.
|
 |
|
|
|
|
 |
H.Ji,
B.Z.Stanton,
J.Igarashi,
H.Li,
P.Martásek,
L.J.Roman,
T.L.Poulos,
and
R.B.Silverman
(2008).
Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors.
|
| |
J Am Chem Soc,
130,
3900-3914.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Babaoglu,
A.Simeonov,
J.J.Irwin,
M.E.Nelson,
B.Feng,
C.J.Thomas,
L.Cancian,
M.P.Costi,
D.A.Maltby,
A.Jadhav,
J.Inglese,
C.P.Austin,
and
B.K.Shoichet
(2008).
Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase.
|
| |
J Med Chem,
51,
2502-2511.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.Kolb,
C.B.Kipouros,
D.Huang,
and
A.Caflisch
(2008).
Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors.
|
| |
Proteins,
73,
11-18.
|
 |
|
|
|
|
 |
G.Siegal,
E.Ab,
and
J.Schultz
(2007).
Integration of fragment screening and library design.
|
| |
Drug Discov Today,
12,
1032-1039.
|
 |
|
|
|
|
 |
H.Jhoti,
A.Cleasby,
M.Verdonk,
and
G.Williams
(2007).
Fragment-based screening using X-ray crystallography and NMR spectroscopy.
|
| |
Curr Opin Chem Biol,
11,
485-493.
|
 |
|
|
|
|
 |
M.F.Rega,
M.Leone,
D.Jung,
N.J.Cotton,
J.L.Stebbins,
and
M.Pellecchia
(2007).
Structure-based discovery of a new class of Bcl-xL antagonists.
|
| |
Bioorg Chem,
35,
344-353.
|
 |
|
|
|
|
 |
P.J.Hajduk
(2006).
Puzzling through fragment-based drug design.
|
| |
Nat Chem Biol,
2,
658-659.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |